Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10.

نویسندگان

  • John M Ford
  • Lisa Rojkjaer
چکیده

Masera and colleagues recently published case reports of lens opacities in three patients with b-thalassemia major that were suggested to be associated with exposure to deferasirox (ICL670, Exjade); the opacities developed 7, 16 and 26 months after initiating deferasirox therapy. These three patients are from a total of 12 being followed by the authors at their institution. This reported incidence of new lens opacity development (25%) during deferasirox treatment is much greater than that observed in the overall population of patients who have received deferasirox in clinical trials, where ophthalmologic monitoring was performed at regular intervals. Of the 1034 patients in the five pivotal studies (whose mean treatment duration was 140 weeks with a cut-off date for follow-up of March 31, 2007) only sixteen (1.5%), including the three reported by Masera, experienced cataracts or lens opacities; most of these were considered by the respective investigator to be unrelated to deferasirox treatment. The authors do not explain or discuss the marked difference in incidence of lens opacities at their center when compared with the overall trial population. Deferasirox treatment was subsequently discontinued in all three patients described by Masera and treatment was switched to combined therapy with deferoxamine (DFO) and deferiprone. Patient #1 experienced new anterior opacities in the left and right eyes 22 and 36 months, respectively, after discontinuing deferasirox; while in patient #2 the initial opacity doubled 14 months after discontinuing deferasirox. If the original opacities were associated with deferasirox treatment the causes of these new opacities, which occurred many months after therapy was discontinued, are unclear and could equally be attributed to treatment with DFO and/or deferiprone. These data highlight the controversy surrounding the issue of lens opacities and chelation therapy, which is not adequately addressed in this article. The authors state that 11–14% of β-thalassemia major patients treated with DFO develop retinopathy and/or lens opacities. However, these percentages are based on small patient numbers (53 and 29 patients, respectively). It is also worth noting that neither of the referenced studies suggest that the lens opacities were related directly to DFO 2 treatment. Some studies have estimated that up to 50% of β-thalassemia patients have ocular abnormalities, including cataracts and acute visual loss, and that the frequency increases with age. Indeed, cataracts/lens opacities have been reported in β-thalassemia patients who had never received chelation therapy, indicating that lens opacities may also be related to iron overload itself or to the underlying disease. One proposed mechanism to account for these findings is increased oxidation of lens protein by reactive iron radicals leading to protein precipitation.6 If the lens opacities are related to chelation therapy, the most widely accepted theory is that they result from over-chelation due to high chelator doses in patients with low serum ferritin levels. However, two of the three patients reported in this paper had high ferritin levels, suggesting that the observed lens opacities were not related to chelation therapy. The authors also mention that no ocular adverse events related to deferiprone treatment have been described; however, to ensure proper data interpretation it is important to know whether such adverse events have been systematically evaluated. In summary, the authors conclude that the three new cases of lens opacities observed at their institution were associated with deferasirox treatment. However, both the current uncertainty surrounding the link between lens opacities and chelation therapy, and the substantially lower incidence rate of lens opacities observed in the overall population of deferasirox-treated patients, suggest that other factors may have also contributed. Ongoing experience with deferasirox from clinical trials and postmarketing use should hopefully shed further light on this issue. Finally, it should be noted that there is an error in the second line of the publication. ather than ‘...treated with deferasirox (DFO) develops...’ it should read ‘...treated with deferoxamine (DFO) develops...’

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.

Introduction About the 11-14% of patients with thalassemia major (TM) treated with deferasirox (DFO) develops retinopathy and/or lens opacities with an unclear pathogenesis but with a clear age related pattern. Possible causes can be either iron overload itself or DFO toxicity, with various mechanisms. No ocular side effects related to L1 are described. During the core study referring to one ye...

متن کامل

Iron chelator drugs in thalassemia,a review article

Abstract Thalassemia syndromes are the most common inherited hemoglobinopathies in the world characterized by various degrees of defective production of the alpha or beta globin chains. Impairment in alpha chain or beta chain synthesis leads to alpha thalassemia and beta thalassemia syndromes respectively. Iran is one of the countries located on the thalassemia belt therefore this disease is ...

متن کامل

Sequential Deferoxamine - Deferasirox in Treatment of Major Thalassemia with Iron Overload

Abstract Background Iron overload is a major problem in patients with major thalassemia. An effective and safe iron chelator protocol with high compliance rate plays an important role in treatment of these patients. This study was done to assess the efficacy and safety of the sequential deferoxamine and deferasirox protocol in major thalassemia patients in Khuzestan province, Iran. Material ...

متن کامل

Efficacy of Deferasirox (Exjade®) versus Osveral® in Treatment of Iron Overload in Patients with Beta- thalassemia Major in Iran; A Non-randomized Controlled Trial

Background: Iron chelators are an important part of management of patients with thalassemia. It is prudent to compare efficacy of different iron chelators in treatment of iron overload in these patients who receive regular blood transfusion. We aimed to compare the efficacy and safety of available oral iron chelator; Deferasirox (Exjade®) with Deferasirox (Osveral®) in reducing iron ove...

متن کامل

Combined Therapy with Deferiprone and Desferrioxamine as Compared to Desferasirox on Ventricular Function in Thalassemia Major Patients

Abstract Background Myocardial iron overload is the leading cause of death in patients with beta-thalassemia major. Combined therapy with deferiprone(DFP) and desferrioxamine (DFO)were suggested to be more effective than deferasirox(DFX) for removing heart iron. Deferasirox has recently been made available, but its long-term efficacy on cardiac function has not yet been established. Our study...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Haematologica

دوره 93 6  شماره 

صفحات  -

تاریخ انتشار 2008